Global Non-Small Cell Lung Cancer (NSCLC) Market

Global Non-Small Cell Lung Cancer (NSCLC) Market Size Insights Forecasts to 2035

• The Global Non-Small Cell Lung Cancer (NSCLC) Market Size Was Estimated at USD 30.02 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.05 % from 2025 to 2035
• The Worldwide Non-Small Cell Lung Cancer (NSCLC) Market Size is Expected to Reach USD 70.35 Billion by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Rreport Published by Decisions Advisors and Consulting, The Global Non-Small Cell Lung Cancer (NSCLC) Market Size was worth around USD 30.02 Billion in 2024 and is predicted to Grow to around USD 70.35 Billion by 2035 with a compound annual growth rate (CAGR) of 8.05 % from 2025 to 2035. Developing immunotherapies and targeted medications, boosting the usage of biomarker testing, enhancing early detection technologies, and increasing access to customized treatment options globally are all opportunities in the non-small cell lung cancer market.

Market Overview

The global treatment, diagnostic, and supportive care ecosystem for non-small cell lung cancer (NSCLC) is a part of the NSCLC Market and represents around 85% of all cases of lung cancer. There are three histologic types of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The non-small cell lung cancer market is made up of companies that manufacture and sell pharmaceutical products as well as development companies that develop and manufacture combination therapy, immunotherapy solutions, chemotherapy agents, and targeted agents with the goal of improving patient quality of life. Additionally, it includes diagnostic products, i.e., biomarker tests, molecular profiling, and imaging technologies, which allow for early detection of cancer and individualized therapies based on the results of these tests. For instance, in July 2025, Thermo Fisher Scientific announced the FDA approval of the Oncomine Dx Express Test, which allows for a 1-day genomic profile and for the detection of EGFR exon 20 insertions for the appropriate use of ZEGFROVY in order to provide precision treatment for the non-small cell lung cancer market. The non-small cell lung cancer market is becoming increasingly biomarker-driven, and the increased need for innovative cancer treatment options is likely to drive the continued growth due to the rapid increase in the incidence of non-small cell lung cancer worldwide.  

Report Coverage

This research report categorizes the non-small cell lung cancer (NSCLC) market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the non-small cell lung cancer (NSCLC) market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the non-small cell lung cancer (NSCLC) market.        

Driving Factors   

The demand for cutting-edge diagnostic and treatment solutions is still rising due to this expanding patient population. The quick development of precision medicine is another important factor. With genomic profiling, biomarker testing, and companion diagnostics having advanced, clinicians can find actionable mutations like EGFR, ALK, and ROS1 and modify treatment regimens accordingly. Targeted treatment adoption is significantly driven by the FDA's recent approval of expanded osimertinib for stage III disease, evacetrapib for MET-altered tumors, and vedotin-tllv for metastatic non-squamous NSCLC. The market for non-small cell lung cancer (NSCLC) is expected to rise steadily due to increased global healthcare engagement, growing clinical Type of Drug Class, and scientific innovation.  

Restraining Factors   

The widespread usage and optimal management of non-small cell lung cancer are restricted by high treatment costs, limited access to advanced diagnostics, variable availability of biomarker testing, regulatory impediments, and severe side effects from immunotherapies and targeted medicines.

Market Segmentation        

The non-small cell lung cancer (NSCLC) market share is classified into the type of therapy, type of drug class, and end user.       

• The combination therapies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.            

Based on the type of therapy, the non-small cell lung cancer (NSCLC) market is divided into monotherapies therapies and combination therapies. Among these, the combination therapies segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Combination therapies are used due to their clinical efficacy, which is shown to be higher than that of monotherapies. The combination therapies with targeted therapies, immunotherapies, and chemotherapeutic agents have become new treatment choices for the entire spectrum of the patient population.  

• The EGFR inhibitors segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.            

Based on the type of drug class, the non-small cell lung cancer (NSCLC) market is divided into alkylating agents, antimetabolites, EGFR inhibitors, mitotic inhibitors, multi-kinase inhibitors, and others. Among these, the EGFR inhibitors segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The capacity of EGFR inhibitors to target particular epidermal growth factor receptor mutations that promote tumor growth is what motivates them. The market demand is further fueled by the frequency of EGFR inhibitors, especially among Asian populations.

• The hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.       

Based on the end user, the non-small cell lung cancer (NSCLC) market is divided into hospitals, home care, specialty clinics, and others. Among these, the hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hospitals are the centers of cancer treatment because they have great infrastructures, advanced diagnostic tools, and specialized oncology care. The presence of multidisciplinary teams comprising different medical experts gives rise to individualized treatment strategies, which in turn enhance the outcomes of the patients.

Regional Segment Analysis of the Non-Small Cell Lung Cancer (NSCLC) Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the non-small cell lung cancer (NSCLC) market over the predicted timeframe.       

North America is anticipated to hold the largest share of the non-small cell lung cancer (NSCLC) market over the predicted timeframe. North America is recognized for possessing the world's most sophisticated health care system, the largest and most developed pharmaceutical and biotech sectors, and the quickest uptake of the newest medicinal and diagnostic technology. Growth in the market is also fueled by high patient and healthcare provider awareness of early detection, precision medicine, and tailored medicines. Significant investments in research and development, continuing clinical trials, and regulatory support, including accelerated clearances from organizations like the U.S. Food and Drug Administration (FDA), all help the region. For Instance, in July 2025, Nuvalent, Inc. launched an announcement for a web and telephonic interview on June 24 to present ARROS-1 Phase 1/2 trial data of zidesamtinib, a ROS1 inhibitor, for TKI pre-treated advanced ROS1-positive Non-Small Cell Lung Cancer.   

Asia Pacific is expected to grow at a rapid CAGR in the non-small cell lung cancer (NSCLC) market during the forecast period. the Asia Pacific region's growth is a greater understanding of early detection, lung cancer's increasing incidence, and better healthcare systems in developing countries such as China, India, and Japan. Furthermore, the rising adoption of high-tech diagnostic tools like molecular profiling, biomarker testing, and next-generation sequencing is speeding up the process of personalized therapy methods in the region. Moreover, in April 2025, Biocon Biologics launched Jobevne™ (bevacizumab-nwgd), a biosimilar to Avastin®, for the treatment of multiple cancers, including non-squamous Non-Small Cell Lung Cancer, thus greatly enhancing the availability of effective targeted treatments.

Competitive Analysis:     

The report offers the appropriate analysis of the key organizations/companies involved within the non-small cell lung cancer (NSCLC) market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.   

List of Key Companies

• AbbVie
• AstraZeneca
• BieGene
• Boehringer Ingelheim
• Daiichi Sankyo
• Eli Lilly and Company
• Gilead Sciences
• GSK
• Merck
• Moderna Therapeutics
• Nuvation Bio
• Pfizer
• Roche
• Johnson & Johnson Innovative Medicine
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In September 2025, Glenmark Pharmaceuticals launched a multi-country Phase 3 clinical trial of Envafolimab, a first-in-class subcutaneous PD-L1 inhibitor, targeting patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) to advance innovative immunotherapy treatments.
• In April 2025, AstraZeneca launched EU approval for Imfinzi (durvalumab) combined with chemotherapy in adults with high-risk resectable Non-Small Cell Lung Cancer (NSCLC), offering neoadjuvant and adjuvant treatment to reduce recurrence and improve surgical outcomes.
• In March 2025, CERo Therapeutics announced that the FDA cleared its second IND for lead compound CER-1236, enabling a Phase 1 clinical trial in advanced solid tumors, including Non-Small Cell Lung Cancer and ovarian cancer.
• In December 2024, Daiichi Sankyo announced that pooled analysis from TROPION-Lung05 Phase II and TROPION-Lung01 Phase III trials showed Datopotamab deruxtecan achieved significant tumor response in previously treated advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer patients.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the non-small cell lung cancer (NSCLC) market based on the below-mentioned segments: 

Global Non-Small Cell Lung Cancer (NSCLC) Market, By Type of Therapy

• Monotherapies Therapies
• Combination Therapies

Global Non-Small Cell Lung Cancer (NSCLC) Market, By Type of Drug Class

• Alkylating Agents
• Antimetabolites
• EGFR Inhibitors
• Mitotic Inhibitors
• Multi-kinase Inhibitors
• Others

Global Non-Small Cell Lung Cancer (NSCLC) Market, By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Non-Small Cell Lung Cancer (NSCLC) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

Frequently Asked Questions (FAQ)

1. What is the CAGR of the non-small cell lung cancer (NSCLC) market over the forecast period?

The global non-small cell lung cancer (NSCLC) market is projected to expand at a CAGR of 8.05% during the forecast period.         

2. What is the market size of the non-small cell lung cancer (NSCLC) market?

The global non-small cell lung cancer (NSCLC) market size is expected to grow from USD 30.02 billion in 2024 to USD 70.35 billion by 2035, at a CAGR of 8.05 % during the forecast period 2025-2035. 

3. Which region holds the largest share of the non-small cell lung cancer (NSCLC) market?

North America is anticipated to hold the largest share of the non-small cell lung cancer (NSCLC) market over the predicted timeframe.           

4. Who are the top 10 companies operating in the global non-small cell lung cancer (NSCLC) market?

AbbVie, AstraZeneca, BieGene, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and Company, Gilead Sciences, GSK, Johnson & Johnson Innovative Medicine, Merck, Moderna Therapeutics, Nuvation Bio, Pfizer, Roche, and Others.

5. What factors are driving the growth of the non-small cell lung cancer (NSCLC) market?

Rising lung cancer prevalence, improvements in targeted medicines and immunotherapies, growing precision medicine acceptance, better diagnostics, and growing healthcare infrastructure worldwide are all factors driving the growth of the NSCLC market.

6. What are the market trends in the non-small cell lung cancer (NSCLC) market?

The development of customized medicines, the increasing use of biomarker-driven treatments, the acceptance of immunotherapy combinations, the growth of companion diagnostics, and the incorporation of digital health into oncology care are all trends in the NSCLC market.

7. What are the main challenges restricting the wider adoption of the non-small cell lung cancer (NSCLC) market?         

Challenges limiting NSCLC market adoption include high treatment costs, limited access to advanced diagnostics, variability in biomarker testing, stringent regulatory requirements, treatment-related adverse effects, and disparities in global healthcare access.